GLG News Analyses of the following article:
Plexxikon announces PLX4032 Phase I Data showing objective responses in metastatic melanoma patients
Published at: www.plexxikon.com
-
PLX-4032, the new great hope for targeted therapy in melanoma
July 27, 2009
PLX-4032, a Plexxikon drug being co-developed with Roche, has shown remarkable results in a Phase I trial for melanoma and appears poised for rapid progression through Phase II and Phase III testing with perhaps accelerated FDA approval on the horizon.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.